[Erythema multiforme following COVID-19 vaccination (BNT162b2)]

Area of Science:

• Dermatology
• Vaccinology
• Infectious Diseases

Background:

• COVID-19 vaccination is crucial for public health.
• Adverse reactions to vaccines, though rare, require thorough investigation.
• Erythema multiforme major is an acute mucocutaneous hypersensitivity reaction.

Observation:

• A case of erythema multiforme major is presented.
• The patient received the second dose of the mRNA vaccine BNT162b2 (Comirnaty).
• Skin and mucous membrane lesions appeared 48 hours post-vaccination.

Findings:

• The patient presented with characteristic lesions of erythema multiforme major.
• The onset of the reaction was temporally associated with the COVID-19 vaccination.
• Complete resolution of lesions was achieved within 3 weeks.

Implications:

• This case highlights a potential, albeit rare, adverse reaction to mRNA COVID-19 vaccines.
• Further monitoring and research are needed to understand the incidence and mechanisms of vaccine-related cutaneous reactions.
• Physicians should be aware of this potential side effect when managing patients post-vaccination.